The Göteborg group in Sweden have just published long-term follow-up data on the management of > 450 men identified with very low-, low-, and intermediate-risk prostate cancer as a consequence of the Gotebörg screening trial and managed on something they call “active surveillance” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, design, outcome, protocol, risk, surveillance | 8 Comments »
A new article from the group at Johns Hopkins has now confirmed that rates of prostate cancer-specific mortality and progression to metastatic disease are extremely low at 15 years of follow-up in their 18-year-long active surveillance cohort. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, Johns Hopkins, outcomes, protocol, surveillance | 12 Comments »
At a 4-hour meeting yesterday afternoon here in New Orleans there was intense discussion of issues related to the future of focal therapy and (potentially) to the approval of new types of device and technologies that might be able to deliver focal therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: eligibility, focal, future, protocol, therapy, trial | 1 Comment »
The fact of the matter is that, as yet, we don’t have a good answer for this question, and it may be many years before we do. The reasons for this are numerous, but we are beginning to get some of the information we need to clarify the situation. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, Johns Hopkins, monitoring, outcomes, PRIAS, protocol, Sunnybrook | 8 Comments »
Recent research data raise questions as to whether clinical trial protocols — and their results — are being skewed (notably for men with so-called “intermediate-risk” disease) by current definitions of risk category. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: category, design, protocol, risk, trial | Leave a comment »
Today’s news reports cover items on:
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: active surveillance, androgen deprivation, biopsy, cardiovasular, castration-resistant prostate cancer, complete, CRPC, hormone therapy, intermittent, marker, protocol, side effects, surrogate | Leave a comment »
